Analysts expect that NuVasive, Inc. (NASDAQ:NUVA) will report sales of $258.85 million for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for NuVasive’s earnings. The lowest sales estimate is $255.70 million and the highest is $262.30 million. NuVasive posted sales of $239.65 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 8%. The company is scheduled to report its next quarterly earnings report on Tuesday, October 24th.

On average, analysts expect that NuVasive will report full year sales of $258.85 million for the current financial year, with estimates ranging from $1.06 billion to $1.07 billion. For the next year, analysts forecast that the company will post sales of $1.16 billion per share, with estimates ranging from $1.15 billion to $1.19 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research analysts that cover NuVasive.

NuVasive (NASDAQ:NUVA) last posted its earnings results on Thursday, July 27th. The medical device company reported $0.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.44 by $0.02. The business had revenue of $260.60 million for the quarter, compared to analysts’ expectations of $261.95 million. NuVasive had a net margin of 3.50% and a return on equity of 13.04%. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.40 earnings per share.

A number of equities research analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of NuVasive in a research note on Friday, July 28th. Royal Bank Of Canada raised their target price on shares of NuVasive from $76.00 to $85.00 and gave the company an “outperform” rating in a research note on Tuesday, June 6th. Barclays PLC reaffirmed a “buy” rating and issued a $80.00 target price on shares of NuVasive in a research note on Wednesday, August 2nd. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $90.00 target price on shares of NuVasive in a research note on Wednesday, August 9th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $79.00 target price on shares of NuVasive in a research note on Sunday, July 30th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $81.18.

In other NuVasive news, Director Lesley H. Howe sold 3,970 shares of NuVasive stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $64.64, for a total transaction of $256,620.80. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Peter Michael Leddy purchased 7,850 shares of the firm’s stock in a transaction on Tuesday, August 1st. The shares were acquired at an average cost of $63.88 per share, for a total transaction of $501,458.00. The disclosure for this purchase can be found here. Company insiders own 1.20% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Teachers Advisors LLC boosted its position in shares of NuVasive by 205.8% in the first quarter. Teachers Advisors LLC now owns 249,546 shares of the medical device company’s stock valued at $18,636,000 after buying an additional 167,950 shares in the last quarter. Diversified Trust Co boosted its position in shares of NuVasive by 5.5% in the second quarter. Diversified Trust Co now owns 6,595 shares of the medical device company’s stock valued at $507,000 after buying an additional 345 shares in the last quarter. NN Investment Partners Holdings N.V. boosted its position in shares of NuVasive by 23.8% in the second quarter. NN Investment Partners Holdings N.V. now owns 38,539 shares of the medical device company’s stock valued at $2,964,000 after buying an additional 7,412 shares in the last quarter. Keybank National Association OH boosted its position in shares of NuVasive by 0.7% in the first quarter. Keybank National Association OH now owns 12,667 shares of the medical device company’s stock valued at $946,000 after buying an additional 86 shares in the last quarter. Finally, Geneva Advisors LLC boosted its position in shares of NuVasive by 3.3% in the second quarter. Geneva Advisors LLC now owns 17,369 shares of the medical device company’s stock valued at $1,336,000 after buying an additional 555 shares in the last quarter.

Shares of NuVasive (NUVA) opened at 61.20 on Tuesday. NuVasive has a 52 week low of $56.70 and a 52 week high of $81.68. The company has a market capitalization of $3.11 billion, a PE ratio of 96.38 and a beta of 1.06. The firm’s 50-day moving average is $70.61 and its 200 day moving average is $73.61.

COPYRIGHT VIOLATION WARNING: “NuVasive, Inc. (NUVA) Expected to Announce Quarterly Sales of $258.85 Million” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.watchlistnews.com/nuvasive-inc-nuva-expected-to-announce-quarterly-sales-of-258-85-million/1529475.html.

About NuVasive

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Get a free copy of the Zacks research report on NuVasive (NUVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.